
    
      The safety and immunogenicity of the vaccine with the antigen NY-ESO-1 in combination with
      the MPLA will be evaluated in a phase 1 clinical trial conducted in patients with
      malignancies that express the antigen (lung, ovarian and melanoma). This study will involve
      15 patients, who will receive 250 mcg of NY-ESO-1 and 100 mcg of MPLA.
    
  